Strong Revenue Growth in Sanara Surgical Segment
The Sanara Surgical segment delivered net revenue of $25.8 million in Q2 2025, representing 28% growth year-over-year, driven by soft tissue products and bone fusion products.
Improved Profitability and Cash Flow
Sanara Surgical achieved $500,000 of net income, an improvement of $2.7 million. Adjusted EBITDA increased by 239% to $4.7 million. The company also generated $2.7 million of cash flow from operating activities in Q2.
Expansion of Commercial Strategy
The company expanded its customer base to over 1,400 healthcare facilities and increased its distributor network to more than 400 partners.
Product Development Milestones
BMI achieved two key development milestones for the OsStic product, keeping the company on track for a Q1 2027 launch.
Clinical Evidence Expansion
Four new clinical manuscripts related to CellerateRx and BIASURGE were submitted to academic journals, enhancing the clinical evidence portfolio.